Marksans pharma Limited has announced the opening of a special window for shareholders to re-lodge transfer requests for physical shares, following regulatory guidelines from the Securities and Exchange Board of India. The initiative addresses long-pending transfer issues for shares purchased or sold before April 1, 2019.

SEBI Regulatory Framework

The special window operates under SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The regulatory framework specifically targets transfer deeds that were previously rejected, returned, or not attended to due to deficiencies in transfer documents or other procedural issues.

Transfer Process and Requirements

Shareholders seeking to utilize this facility must submit comprehensive documentation to ensure proper transfer registration. The company has specified that successful transfers will result in shares being credited exclusively in demat mode, with no physical share certificates issued.

The mandatory documentation requirements include:

• Original share certificate
• Transfer deed executed prior to April 1, 2019
• Proof of purchase by transferee
• KYC documents of the transferee as per ISR forms
• Latest Client Master List of the demat account, duly attested by the depository participant
• Undertaking cum Indemnity in prescribed format
• Additional documents as required on case-by-case basis

Lock-in Period and Restrictions

Transferred shares will be subject to specific restrictions designed to ensure regulatory compliance. The company has outlined clear parameters for share movement post-transfer.

Contact Information and Support

Shareholders requiring assistance can contact the company's Registrar and Share Transfer Agent, Bigshare Services Private Limited, located at Office No. S6-2, 6th Floor, Pinnacle Business Park, Andheri (East), Mumbai – 400093. The RTA can be reached at 022 62638200 or via email at info@bigshareonline.com .

For direct company queries, shareholders may contact the Company Secretary at companysecretary@marksanspharma.com or reach Mr. Atul Shukla at 022 4001 2000. The undertaking cum indemnity format can be downloaded from the company's website at www.marksanspharma.com .

Marksans Pharma Limited delivered robust Q3 FY26 financial results, achieving record quarterly operating revenue of INR 754.4 crores and demonstrating strong operational performance across key markets. The pharmaceutical company's earnings conference call on February 06, 2026, revealed sustained growth momentum despite pricing pressures in certain segments.

Financial Performance Highlights

The company's Q3 FY26 performance showcased significant improvements across multiple financial metrics. Operating revenue grew 10.6% year-on-year, marking an all-time high for the quarter despite high single-digit price erosion in prescription product segments.

Gross margins expanded significantly by 184 basis points to 58.1% compared to 56.2% in the previous year, attributed to softening raw material prices, favorable product mix, and foreign exchange benefits. EBITDA margins improved substantially by 217 basis points year-on-year to 21.3%.

Geographic Revenue Performance

The US and North American markets emerged as the primary growth driver, delivering strong performance supported by seasonal demand and robust order execution.

The UK and EU formulation business remained flat year-on-year as pricing pressures persisted, though the company reported sequential stability and recovery supported by new product launches and favorable currency movements.

Nine-Month Performance Overview

For the nine-month period ending December 2025, Marksans Pharma achieved operating revenue of INR 2,094.8 crores, up 9.4% from INR 1,914.4 crores in the corresponding period last year.

Strategic Expansion and Product Pipeline

The company strengthened its global footprint through strategic initiatives and regulatory approvals. Marksans incorporated new subsidiaries including Marksans Europe Limited in Ireland and Marksans Canada Inc., positioning for future growth in regulated markets.

Key regulatory achievements during the quarter included:

• MHRA market authorization for multiple products in the UK, including mefenamic acid tablets and cetirizine oral solutions
• USFDA approval for amide hydrochloride, enhancing presence in high-velocity OTC categories
• Continued focus on pain, allergy, GI, and cough and cold therapeutic segments

The company maintained a strong US order book exceeding $220 million, supporting future revenue visibility and growth prospects.

Financial Position and Outlook

Marksans Pharma continues to maintain a debt-free balance sheet with cash reserves of INR 824.2 crores as of December 31, 2025. The company invested INR 97 crores in capex during the nine-month period while maintaining steady working capital at 151 days.

Management outlined strategic milestones targeting INR 4,000 crores in revenue within the next 2-3 years, driven by current portfolio performance and market expansion initiatives. The company's R&D investment of 3% of consolidated revenue supports continued product pipeline development and regulatory filings across multiple geographies.